| Nov 18 |
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial
|
| Nov 18 |
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
|
| Nov 18 |
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy
|
| Nov 15 |
Regenxbio down 13% ahead of data readout for muscular dystrophy asset
|
| Nov 14 |
Regenxbio up after announcement of pivotal program data
|
| Nov 14 |
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
|
| Nov 9 |
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report
|
| Nov 8 |
REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations
|
| Nov 7 |
Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...
|
| Nov 7 |
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
|
